KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2018 - 2025)

Acadia Pharmaceuticals has reported Other Non-Current Liabilities over the past 10 years, most recently at $19.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $19.1 million for Q4 2025, up 5.99% from a year ago — trailing twelve months through Dec 2025 was $19.1 million (up 5.99% YoY), and the annual figure for FY2025 was $19.1 million, up 5.99%.
  • Other Non-Current Liabilities for Q4 2025 was $19.1 million at Acadia Pharmaceuticals, up from $13.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ACAD hit a ceiling of $28.5 million in Q2 2025 and a floor of $3.6 million in Q1 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $10.3 million (2023), compared with a mean of $11.3 million.
  • Peak annual rise in Other Non-Current Liabilities hit 130.93% in 2025, while the deepest fall reached 9.35% in 2025.
  • Acadia Pharmaceuticals' Other Non-Current Liabilities stood at $7.0 million in 2021, then increased by 29.0% to $9.1 million in 2022, then surged by 66.93% to $15.1 million in 2023, then grew by 19.21% to $18.1 million in 2024, then grew by 5.99% to $19.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $19.1 million (Q4 2025), $13.9 million (Q3 2025), and $28.5 million (Q2 2025) per Business Quant data.